Abstract: A footwear sole assembly with upper and lower layers, where the upper layer has a firmer durometer than the lower layer. Upon a user's heel strike, the difference in resilience between the upper and lower layers causes the upper layer to compress the lower layer. Sidewalls in the upper layer are urged toward each other on the heel strike, providing cradling support for the user's heel. The rigidness of the sidewalls of the upper layer also encourages the foot to propel through the stride, especially with the addition of a rolling element along the side of the footwear.

Abstract: A sole assembly for footwear includes a footbed made of a first resilient material with a lower durometer than a surrounding rocker frame composed of a second resilient material. During a user's heel-to-toe motion, medial and lateral rolling elements extending downward from the frame form convex longitudinal curves from heel to midfoot, guiding the transition from heel strike to toe-off. Beneath the footbed, a rigid support plate with medial and lateral extensions is incorporated to provide torsional stability and to restrict forefoot flexion, reducing pronation and supination while centering the foot. As a result, energy is stored during gait and released to propel the user, supporting a controlled, dynamic rolling gait during walking or running.

Abstract: A footwear sole assembly with upper and lower layers, where the upper layer has a firmer durometer than the lower layer. Upon a user's heel strike, the difference in resilience between the upper and lower layers causes the upper layer to compress the lower layer. Sidewalls in the upper layer are urged toward each other on the heel strike, providing cradling support for the user's heel. The rigidness of the sidewalls of the upper layer also encourages the foot to propel through the stride, especially with the addition of a rolling element along the side of the footwear.

Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs) comprising CD70 binding domains, T cells engineered to express one or more TFPs, antibodies that specifically bind CD70, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Provided herein are recombinant nucleic acids encoding a T cell receptor (TCR) fusion protein (TFP) and an interleukin-15 (IL-15) polypeptide and/or an interleukin-15 receptor alpha (IL-15R?) polypeptide, modified T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Disclosed herein are methods for treatment of a mesothelin (MSLN)-expressing cancer in a human subject comprising administration of, e.g., a plurality of anti-MSLN T cell receptor fusion protein (TFP)-expressing T cells. A ratio of CD4+ to CD8+ T cells in a sample from the human subject may have been determined before the administration of the plurality of anti-MSLN TFP-expressing T cells. The plurality of anti-MSLN TFP-expressing T cells may comprise a pre-determined ratio of CD4+ to CD8+ T cells.

Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified ?? T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: The invention relates to polypeptides that block or inhibit the interleukin-1 receptor 1 (IL-1R1), the interaction of IL-1beta with IL-1R1 or the interaction between IL-1R1 and interleukin-1 receptor accessory protein (IL-1RaCP). The invention relates specifically to therapeutic polypeptides that target specifically IL-1R1 present on tumor cells, cancer stem cells, and cancer stem cells which are resistant to chemotherapy or radiotherapy. The invention specifically relates to cancer stem cells (CSC) that express IL-1R1 to which said inhibitors bind. Finally the invention relates to a combination therapy comprising killing tumorigenic differentiating cancer cells by means of standard chemo- or radiotherapy and prior or subsequent to that applying IL-1R1 inhibitors which target specifically CSC and strip the tumor of its capacity to generate cancer cell progeny.

Abstract: A footwear sole assembly (10) for walking with a rolling action is described. An elastically compressible midsole element (33) is provided with a rolling element (40) situated in and extending over a portion of the length and over at least a portion of the width of the midsole element (33). The rolling element (40) consists at least partially of a resilient material and is disposed at least in that region of the midsole (33) which is opposite to the arch of the wearer's foot. This shoe offers the rolling gait advantages of the well known MBT shoe, but has a different construction which enables it to retain the outward appearance of conventional shoes such as trainers.

Abstract: A footwear sole assembly (10) for walking with a rolling action is described. An elastically compressible midsole element (33) is provided with a rolling element (40) situated in and extending over a portion of the length and over at least a portion of the width of the midsole element (33). The rolling element (40) consists at least partially of a resilient material and is disposed at least in that region of the midsole (33) which is opposite to the arch of the wearer's foot. This shoe offers the rolling gait advantages of the well known MBT shoe, but has a different construction which enables it to retain the outward appearance of conventional shoes such as trainers.